Scarica l'app Stockscreener
6.36
1.24%
-0.08
Dopo l'orario di chiusura:
6.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.44
Aprire:
$6.47
Volume 24 ore:
636.37K
Relative Volume:
0.27
Capitalizzazione di mercato:
$290.76M
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-7.6627
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
-5.64%
1M Prestazione:
-20.90%
6M Prestazione:
-51.34%
1 anno Prestazione:
+52.15%
Intervallo 1D:
$6.27
$6.47
Intervallo di 1 settimana:
$6.045
$6.77
Portata 52W:
$4.20
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Confronta CAPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.36 | 289.39M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
CAPR FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class ActionCAPR - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - PR Newswire
Capricor Therapeutics (NASDAQ:CAPR) Given "Buy" Rating at HC Wainwright - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - WV News
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, - GlobeNewswire
CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - Barchart.com
CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Octagon Capital Advisors LP Makes New $4.27 Million Investment in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Capricor Therapeutics Files $300 Million Mixed Shelf - MarketScreener
Capricor Therapeutics files for mixed shelf offering of up to $300 million- SEC filing - MarketScreener
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Securities Fraud Class Action Filed Against Capricor Therapeutics, Inc. (CAPR)Levi & Korsinsky Reminds Investors of September 15, 2025 - Barchart.com
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc. - GlobeNewswire
Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - Newsfile
Capricor refutes FDA’s DMD deramiocel rejection in public statement - Yahoo Finance
CAPR DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, - GlobeNewswire
Investors SueWallSt Over Capricor Therapeutics, Inc. Stock DropContact Levi & Korsinsky to Join - ACCESS Newswire
Capricor Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Securities Lawsuit Alert: Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - Barchart.com
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet - simplywall.st
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - Business Wire
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel - GlobeNewswire
CAPR INVESTOR ALERT: Kirby McInerney LLP Notifies Capricor Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit - Business Wire
Levi & Korsinsky Invites Investors to SueWallSt After Capricor Therapeutics, Inc. Stock Collapse - ACCESS Newswire
Shareholders of Capricor Therapeutics, Inc. Should Contact - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) largest shareholders are retail investors with 58% ownership, institutions own 30% - Yahoo Finance
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) should contact The Gross Law Firm about pending Class ActionCAPR - Morningstar
New SueWallSt Podcast Episode: Levi & Korsinsky Breaks Down Capricor Therapeutics, Inc. Case - Louisiana First News
Nuveen LLC Purchases New Shares in Capricor Therapeutics, Inc. $CAPR - MarketBeat
AWM Investment Company Inc. Takes Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
5 Companies Caught on a Carousel of FDA Confusion - BioSpace
CAPR FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class ActionCAPR - ACCESS Newswire
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 15, 2025Contact Levi & Korsinsky - Stockhouse
Faruqi & Faruqi Reminds Capricor Investors of the Pending - GlobeNewswire
User - FinancialContent
Can Capricor Therapeutics Inc. stock double in the next yearJuly 2025 Spike Watch & Comprehensive Market Scan Insights - خودرو بانک
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
CAPR FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, - GlobeNewswire
Silicon Valley - FinancialContent
Short interest data insights for Capricor Therapeutics Inc.Quarterly Portfolio Review & Weekly Hot Stock Watchlists - Newser
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):